Abstract | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant solid tumor that lacks early diagnostic methods. Recently, targeted immunotherapy and radiotherapy have been integrated with radionuclide-antibody conjugate drugs, which can be used for targeted diagnosis and dynamic imaging of tumors. CEACAM6 is overexpressed in pancreatic tumors and is a potential theranostic target for PDAC. We aimed to develop a novel targeted carrier for theranostics of PDAC and other solid tumors. METHODS: Based on camelid heavy-chain-only antibodies, we developed a CEACAM6-targeting recombinant antibody NY004, and evaluated it as a novel antibody-carrier for imaging and therapy of cancer in tumor models. We labeled NY004 with theranostic nuclides and applied this self-developed antibody platform in diagnostic imaging and antitumor assessment in PDAC models. RESULTS: Through microPET, IHC, and biodistribution assays, targeting and biodistribution of [89Zr]-NY004 in solid tumors including PDAC was examined, and the investigated tumors were all CEACAM6-positive malignancies. We found that NY004 was suitable for use as a drug carrier for radioimmunotheranostics. Our study showed that NY004 was characterized by high targeted uptake and a long retention time in PANC-1 tumors (up to 6 days post-injection), with good specificity and high imaging efficiency. Therapeutic evaluation of the radionuclide-labeled antibody drug [177Lu]-NY004 in PDAC tumor-bearing model revealed that NY004 had high and prolonged uptake in tumors, relatively low non-target organ uptake, and good anti- tumor efficacy. CONCLUSION: As a drug platform for radiotheranostics, CEACAM6-specific antibody NY004 met the requirements of easy-labeling, targeting specificity, and effective persistence in pancreatic adenocarcinoma tissues. KEY POINTS: • [89Zr]-NY004 has good specificity and high imaging efficiency, and is characterized by high tumor-targeting uptake and a long tumor retention time as a PET molecular imaging tracer. • Therapeutic radionuclide-conjugated antibody drug [177Lu]-NY004 has high uptake and prolonged uptake duration in tumors, low non-target organ uptake, and significant tumor-inhibiting efficacy in PDAC model. • The self-developed antibody structure NY004 is a promising drug platform for radioimmunotheranostics of CEACAM6-positive tumors including pancreatic ductal adenocarcinoma.
|
Authors | Yanyan Kong, Fang Xie, Zhengwei Zhang, Shaobo Wang, Yabin Zhang, Yang Di, Zhongwen Zhou, Donglang Jiang, Junpeng Li, Qi Huang, Jie Wang, Xiuming Li, Zhiwei Pan, Ruiqing Ni, Yihui Guan |
Journal | European radiology
(Eur Radiol)
Vol. 33
Issue 10
Pg. 7077-7088
(Oct 2023)
ISSN: 1432-1084 [Electronic] Germany |
PMID | 37166496
(Publication Type: Journal Article)
|
Copyright | © 2023. The Author(s), under exclusive licence to European Society of Radiology. |
Chemical References |
|
Topics |
- Humans
- Pancreatic Neoplasms
(diagnostic imaging, therapy, pathology)
- Adenocarcinoma
(pathology)
- Tissue Distribution
- Carcinoma, Pancreatic Ductal
(diagnostic imaging, therapy)
- Positron-Emission Tomography
(methods)
- Radioisotopes
(therapeutic use)
- Cell Line, Tumor
- Pancreatic Neoplasms
|